[´ã´ç¾÷¹«] ´ë±â¾÷ °è¿ Á¦¾à»ç¿¡¼ ¡°Business Development & Evaluation¡± ¾÷¹«¸¦ ÇÏ½Ç ºÐÀ» ã°í ÀÖ½À´Ï´Ù. - ±Ù¹«Áö: °æ±âµµ - Á÷±Þ: »ç¿ø ~ Ã¥ÀÓ
[¼öÇà¾÷¹«] * Pharmaceutical Market ¹× Business ȯ°æÀÇ Intelligence ¹× ºÐ¼® ¾÷¹« --- CNS/Ç×¾Ï µî ȸ»ç ÁÖ¿ä TA¿¡ ´ëÇÑ Market Intelligence¸¦ ÅëÇÑ ¼¼ºÎ BD Àü·« ¼ö¸³ --- ¹ÙÀÌ¿À¡¤Á¦¾à ¾÷°èÀÇ Business Deal, ÀÓ»ó °á°ú µî¿¡ ´ëÇÑ ¸ð´ÏÅ͸µ ¹× ½ÉÃþ Á¶»ç/ºÐ¼® ¼öÇà * Á¦Ç°/Pipeline/Platform TechnologyÀÇ µµÀÔ ÃßÁø Èĺ¸ ¹ß±¼, ºÐ¼®, Æò°¡ --- CNS/Ç×¾Ï ºÐ¾ßÀÇ µµÀÔ ÃßÁø Èĺ¸ Asset ¹× ±â¹Ý ±â¼úÀÇ ¹ß±¼ À§ÇÑ Á¶»ç, ÄÁÆÛ·±½º Âü¼®, ¾÷ü ¹ÌÆà --- À¯°ü ºÎ¼ Çù¾÷ ÅëÇÑ »ó¼¼ °ËÅä (Due Diligence)¹× ¼öÇà, °è¾à¼ Çù»ó µî * Partnering Deal ¼öÇà --- ȸ»ç º¸À¯ Asset¿¡ ´ëÇÑ ÆÄÆ®³Ê¸µ (Licensing-out) Áغñ --- Potential Buyer Ž»ö, ¼±º° ¹× Á¢ÃË, Due Diligence ´ëÀÀ, ÆÄÆ®³Ê¸µ °è¾à¼ Çù»ó µî Deal ÃßÁø
[ÀÚ°Ý¿ä°Ç] - ÇзÂ: ¼®»ç ÀÌ»ó ÇÐÀ§ ¼ÒÁöÀÚ - Àü°ø: »ý¸í°úÇÐ À¯°ü Àü°ø ¶Ç´Â »ý¸í°úÇÐ À¯°ü MBA - °æ·Â: °æ·Â ¸¸ 2³â ~ 10³â - Á¦¾à ¶Ç´Â ÇコÄɾî ȸ»ç Business Development ºÎ¼ ±Ù¹« °æ·Â º¸À¯ÀÚ ¿ì´ë - Á¦¾à ¶Ç´Â ÇコÄɾî ȸ»çLicensing In/Out ºÎ¼ ±Ù¹« °æ·Â º¸À¯ÀÚ ¿ì´ë - CNS/Ç×¾Ï ¿¬±¸ °æ·Â ¹× ÀÓ»ó ¼öÇà °æ·Â º¸À¯ÀÚ ¿ì´ë - Á¦¾à ¶Ç´Â ÇコÄÉ¾î »ê¾÷¿¡¼ÀÇ ½ÃÀå ¹× ¾÷ü, ÆÄÀÌÇÁ¶óÀÎ, Á¦Ç°, ±â¼ú ºÐ¼® °æÇè º¸À¯ÀÚ ¿ì´ë - ±Û·Î¹ú ¼öÁØ ¿µ¾î Ä¿¹Â´ÏÄÉÀÌ¼Ç ´É·Â º¸À¯
Those who are interested in this opportunity, please submit your Resume (CV) in MS Word Format by email urgently. Only qualified candidates will be contacted for interview. All resumes not contacted will be kept in DB confidentially for future positions.
KIM, Kyung Jin (Ian Kim) CEO / Exdigm Inc. M. ***-****-**** E. ceo@exdigm.com******@*******.*** U. www.exdigm.com
[±Ù¹«ºÎ¼ ¹× Á÷±Þ/Á÷Ã¥] Á÷±Þ/Á÷Ã¥: »ç¿ø, ´ë¸®, °úÀå, ÆÀ¿ø
|
[ÀÚ°Ý¿ä°Ç] °æ·Â»çÇ×: °æ·Â(2³â ÀÌ»ó 10³â ÀÌÇÏ) Çз»çÇ×: ¼®»çÁ¹¾÷ Á÷¹«±â¼ú: »ç¾÷°³¹ß, »ç¾÷°èȹ, »ç¾÷Á¦ÈÞ, Á¦¾à
|